Partial adenosine A1 receptor agonists for cardiovascular therapies

Linden J (2005) Adenosine in tissue protection and tissue regeneration. Mol Pharmacol 67:1385–1387. doi: 10.1124/mol.105.011783

Brodde O-E, Michel MC (1999) Adrenergic and muscarinic receptors in the human heart. Pharmacol Rev 51:651–690

Fredholm BB, Ijzerman AP, Jacobson KA, Klotz KN, Linden J (2001) International Union of Pharmacology. XXV. Nomenclature and classification of adenosine receptors. Pharmacol Rev 264:527–552

Mustafa SJ, Morrison RR, Teng B, Pelleg A (2009) Adenosine receptors and the heart: role in regulation of coronary blood flow and cardiac electrophysiology. Handb Exp Pharmacol 193:161–188. doi: 10.1007/978-3-540-89615-9_6

Hussain T, Mustafa SJ (1995) Binding of A1 adenosine receptor ligand [3H]8-cyclopentyl-1,3-dipropylxanthine in coronary smooth muscle. Circ Res 77:194–198

Musser B, Morgan ME, Leid M, Murray TF, Linden J, Vestal RE (1993) Species comparison of adenosine and beta-adrenoceptors in mammalian atrial and ventricular myocardium. Eur J Pharmacol 246:105–111

Van Calker D, Müller M, Hamprecht B (1978) Adenosine inhibits the accumulation of cyclic AMP in cultured brain cells. Nature 276:839–841

Londos C, Cooper DMF, Wolff J (1980) Subclasses of external adenosine receptors. Proc Natl Acad Sci U S A 77:2551–2554

Finegan BA, Lopaschuk GD, Gandhi M, Clanachan AS (1996) Inhibition of glycolysis and enhanced mechanical function of working rat hearts as a result of adenosine A1 receptor stimulation during reperfusion following ischaemia. Br J Pharmacol 118:355–363

Peart J, Headrick JP (2000) Intrinsic A(1) adenosine receptor activation during ischemia or reperfusion improves recovery in mouse hearts. Am J Physiol Heart Circ Physiol 279:H2166–H2175

Headrick JP, Hack B, Ashton KJ (2003) Acute adenosinergic cardioprotection in ischemic-reperfused hearts. Am J Physiol Heart Circ Physiol 285:H1797–H1819. doi: 10.1152/ajpheart.00407.2003285/5/H1797

Reichelt ME, Willems L, Molina JG, Sun CX, Noble JC, Ashton KJ, Schnermann J, Blackburn MR, Headrick JP (2005) Genetic deletion of the A1 adenosine receptor limits myocardial ischemic tolerance. Circ Res 96:363–367. doi: 10.1161/01.RES.0000156075.00127.C3

Ely SW, Berne RM (1992) Protective effects of adenosine in myocardial ischemia. Circulation 85:893–904

Mubagwa K, Flameng W (2001) Adenosine, adenosine receptors and myocardial protection: an updated overview. Cardiovasc Res 52:25–39

Liao Y, Takashima S, Asano Y, Asakura M, Ogai A, Shintani Y, Minamino T, Asanuma H, Sanada S, Kim J, Ogita H, Tomoike H, Hori M, Kitakaze M (2003) Activation of adenosine A1 receptor attenuates cardiac hypertrophy and prevents heart failure in murine left ventricular pressure-overload model. Circ Res 93:759–766. doi: 10.1161/01.RES.0000094744.88220.62

Stone TW, Ceruti S, Abbracchio MP (2009) Adenosine receptors and neurological disease: neuroprotection and neurodegeneration. Handb Exp Pharmacol 193:535–587. doi: 10.1007/978-3-540-89615-9_17

Liang BT, Donovan LA (1990) Differential desensitization of A1 adenosine receptor-mediated inhibition of cardiac myocyte contractility and adenylate cyclase activity. Relation to the regulation of receptor affinity and density. Circ Res 67:406–414

Green A (1987) Adenosine receptor down-regulation and insulin resistance following prolonged incubation of adipocytes with an A1 adenosine receptor agonist. J Biol Chem 262:15702–15707

Lee HT, Thompson CI, Hernandez A, Lewy JL, Belloni FL (1993) Cardiac desensitization to adenosine analogues after prolonged R-PIA infusion in vivo. Am J Physiol 265:H1916–H1927

Roman V, Keijser JN, Luiten PG, Meerlo P (2008) Repetitive stimulation of adenosine A1 receptors in vivo: changes in receptor numbers, G-proteins and A1 receptor agonist-induced hypothermia. Brain Res 29:69–74. doi: 10.1016/j.brainres.2007.11.044

Srinivas M, Shryock JC, Dennis DM, Baker SP, Belardinelli L (1997) Differential A1 adenosine receptor reserve for two actions of adenosine on guinea pig atrial myocytes. Mol Pharmacol 52:683–691

Parsons WJ, Stiles GL (1987) Heterologous desensitization of the inhibitory A1 adenosine receptor-adenylate cyclase system in rat adipocytes. Regulation of both Ns and Ni. J Biol Chem 262:841–847

Longabaugh JP, Didsbury J, Spiegel A, Stiles GL (1989) Modification of the rat adipocyte A1 adenosine receptor-adenylate cyclase system during chronic exposure to an A1 adenosine receptor agonist: alterations in the quantity of GS alpha and Gi alpha are not associated with changes in their mRNAs. Mol Pharmacol 36:681–688

Fatholahi M, Xiang Y, Wu Y, Li Y, Wu L, Dhalla AK, Belardinelli L, Shryock JC (2006) A novel partial agonist of the A1-adenosine receptor and evidence of receptor homogeneity in adipocytes. J Pharmacol Exp Ther 317:676–684. doi: 10.1124/jpet.105.099119

Dhalla A, Santikul M, Smith M, Wong MY, Shryock J, Belardinelli L (2007) Anti-lipolytic activity of a novel partial A1 adenosine receptor agonist devoid of cardiovascular effects: comparison with nicotinic acid. J Pharmacol Exp Ther 321:327–333. doi: 10.1124/jpet.106.114421

Urmaliya VB, Pouton CW, Devine SM, Haynes JM, Warfe L, Scammelis PJ, White PJ (2010) A novel highly selective adenosine A1 receptor agonist VCP28 reduces ischemia injury in a cardiac cell line and ischemia–reperfusion injury in isolated rat hearts at concentrations that do not affect heart rate. J Cardiovasc Pharmacol 56:282–292. doi: 10.1097/FJC.0b013e3181eb8563

Kiesmann WF, Elzain E, Zablocki F (2009) A1 adenosine receptor antagonists, agonists and allosteric enhancers. In: Wilson CN, Mustafa SJ (eds) Handbook of experimental pharmacology 193. Springer, Berlin, pp 25–58

Nell P, Albrecht-Küpper B (2009) The adenosine A1 receptor and its ligands. In: Lawton G, Witty DR (eds) Progress in medicinal chemistry. Elsevier, Amsterdam, pp 164–201. doi: 10.1016/S0079-6468(08)00204-X

Lorenzen A, Fuss M, Vogt H, Schwabe U (1993) Measurement of guanine nucleotide-binding protein activation by A1 adenosine receptor agonists in bovine brain membranes: stimulation of guanosine-5′-O-(3[35S]thio)triphosphate binding. Mol Pharmacol 44:115–123

Lorenzen A, Guerra L, Vogt H, Schwabe U (1996) Interaction of full and partial agonists of the a1 adenosine receptor with receptor/G protein complexes in rat brain membranes. Mol Pharmacol 49:915–926

Rosentreter U, Krämer T, Shimada M, Hübsch W, Diedrichs N, Krahn T, Henninger K, Stasch JP, Wischnat R (2003) PCT Int Appl, WO 03 053441 CAN 139:36542

Wu L, Belardinelli L, Zablocki JA, Palle V, Shryock JC (2001) A partial agonist of the A(1)-adenosine receptor selectively slows AV conduction in guinea pig hearts. Am J Physiol 280:H334–H343

Aderis Pharmaceuticals. Safety and efficacy study of an A1-adenosine receptor agonist to slow heart rate in atrial fibrillation 2005. Available from: http//: www.clinicalstrials.gov./ct/show/NCT00040001?order=1

Bayer Schering Pharma AG (2007) Clinical study in ClinicalTrials.gov identifier NCT00568945. Bayer Schering Pharma AG, Wuppertal

Zablocki JA, Wu L, Shryock JC, Belardinelli L (2004) Partial A1 adenosine receptor agonists from a molecular perspective and their potential use as chronic ventricular rate control agents during atrial fibrillation (AF). Curr Top Med Chem 4:839–854

Otani H (2008) Ischemic preconditioning: from molecular mechanisms to therapeutic opportunities. Antioxid Redox Signal 10:207–247. doi: 10.1089/ars.2007.1679

Baxter GF (2002) Role of adenosine in delayed preconditioning of myocardium. Cardiovasc Res 55:483–494

Thornton JD, Liu GS, Olsson RA, Downey JM (1992) Intravenous pretreatment with A1-selective adenosine analogues protects the heart against infarction. Circulation 85:659–665

Headrick JP, Lasley RD (2009) Adenosine receptors and reperfusion injury of the heart. Handb Exp Pharmacol 193:189–214. doi: 10.1007/978-3-540-89615-9_7

Sommerschild HT, Kirkebøen KA (2002) Preconditioning—endogenous defence mechanisms of the heart. Acta Anaesthesiol Scand 46:123–137

Hausenloy DJ, Yellon DM (2006) Survival kinases in ischemic preconditioning and postconditioning. Cardiovasc Res 70:240–253. doi: 10.1016/j.cardiores.2006.01.017

Dana A, Baxter GF, Walker JM, Yellon DM (1998) Prolonging the delayed phase of myocardial protection: repetitive adenosine A1 receptor activation maintains rabbit myocardium in a preconditioned state. J Am Coll Cardiol 31:1142–1149

Peart JN, Gross GJ (2003) Adenosine and opioid receptor-mediated cardioprotection in the rat: evidence for cross-talk between receptors. Am J Physiol Heart Circ Physiol 285:H81–H89. doi: 10.1152/ajpheart.00985.200200985.2002

Tendera M, Sosnowski M, Gaszewska-Zurek E, Parma Z, Neuser D, Seman L (2007) The oral adenosine A1 receptor agonist, BAY 68-4986, reduces heart rate at peak exercise in patients with chronic stable angina. J Am Coll Cardiol 49(suppl A):232A

Dhalla AK, Shryock JC, Shreeniwas R, Belardinelli L (2003) Pharmacology and therapeutic applications of A1 adenosine receptor ligands. Curr Top Med Chem 3:369–385